17th International Congress on Infectious Diseases
17thICID_FinalProg
17thICID_FinalProg
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<str<strong>on</strong>g>17th</str<strong>on</strong>g> INTERNATIONAL CONGRESS ON INFECTIOUS DISEASES<br />
Scientific Program ~ Thursday, March 3, 2016<br />
THURSDAY • March 3, 2016<br />
Meet-the-Expert Sessi<strong>on</strong>s<br />
Thursday, March 3, 2016 07:45–08:45<br />
Clinical Case Discussi<strong>on</strong>s<br />
CME<br />
for Trainees<br />
– V. Gant, United Kingdom Room: Hall 2<br />
Why Isn’t Mathematical<br />
CME<br />
Modeling Being Utilized<br />
to Inform <strong>Infectious</strong> Disease<br />
Public Health Policy?<br />
– M. Roberts, USA Room: G.01–03<br />
The Value of Adult Vaccinati<strong>on</strong><br />
In collaborati<strong>on</strong> with MSD<br />
– Herpes Zoster Management Room: G.05–06<br />
J. Litt, Australia<br />
– Pneumococcal Disease in Adults Room: G.05–06<br />
D. Feds<strong>on</strong>, France<br />
Sessi<strong>on</strong> 01<br />
Plenary I<br />
Streptococcal Lymphatic Metastasis:<br />
Bacterial Close Encounters of the<br />
Fourth Kind<br />
Chair: Keith Klugman, USA<br />
CME<br />
Room: Hall 4 (Plenary Hall) 09:00–09:45<br />
Ground Floor Thursday, March 3, 2016<br />
01.001 Streptococcal lymphatic metastasis: Bacterial<br />
close encounters of the fourth kind<br />
S. Sriskandan<br />
L<strong>on</strong>d<strong>on</strong> (United Kingdom)<br />
Coffee Break<br />
Exhibiti<strong>on</strong>/Hall 3 09:45–10:15<br />
Ground Floor Thursday, March 3, 2016<br />
Sessi<strong>on</strong> 02<br />
Symposium<br />
Preventi<strong>on</strong> of Childhood Pneum<strong>on</strong>ia<br />
Through Vaccinati<strong>on</strong><br />
Co-Chairs: Keith Klugman, USA<br />
N.K. Ganguly, India<br />
CME<br />
Room: Hall 1 10:15–12:15<br />
Ground Floor Thursday, March 3, 2016<br />
02.001 Global burden of pneum<strong>on</strong>ia<br />
K. Thomas<br />
Vellore (India)<br />
02.002 Community-acquired pneum<strong>on</strong>ia in children<br />
under five years of age: An overview<br />
S. Awashti<br />
Lucknow (India)<br />
02.003 Preventi<strong>on</strong> of childhood pneum<strong>on</strong>ia through<br />
vaccinati<strong>on</strong><br />
R. Dagan<br />
Beer-Sheva (Israel)<br />
02.004 The path to pneum<strong>on</strong>ia preventi<strong>on</strong> in India—<br />
Call to acti<strong>on</strong><br />
R. Kumar<br />
New Delhi (India)<br />
In collaborati<strong>on</strong> with the<br />
Bill & Melinda Gates Foundati<strong>on</strong><br />
Sessi<strong>on</strong> 03<br />
Integrated Symposium<br />
Potential Role of Dengue Vaccinati<strong>on</strong><br />
in Integrated Disease Preventi<strong>on</strong><br />
and C<strong>on</strong>trol<br />
Co-Chairs: Ashutosh Biswas, India<br />
Gathsaurie Neelika Malavige, Sri Lanka<br />
Room: Hall 2 10:15–12:15<br />
Ground Floor Thursday, March 3, 2016<br />
03.001 The burden of dengue: Insights from large<br />
scale clinical studies<br />
O. Brady<br />
Oxford (United Kingdom)<br />
03.002 Recent update <strong>on</strong> dengue vaccine<br />
development<br />
P. Pitisuttithum<br />
Bangkok (Thailand)<br />
03.003 Dengue vaccinati<strong>on</strong> impact:<br />
Perspective from modeling<br />
T. Hladish<br />
Gainesville, FL (USA)<br />
03.004 Roadmap for dengue vaccinati<strong>on</strong><br />
introducti<strong>on</strong> in Mexico<br />
M. Betancourt-Cravioto<br />
Mexico City (Mexico)<br />
Developed in collaborati<strong>on</strong> with and supported by<br />
an educati<strong>on</strong>al grant from Sanofi Pasteur<br />
28 ~ FINAL PROGRAM #<str<strong>on</strong>g>17th</str<strong>on</strong>g>ICID
Change language